Phase 3, randomized, international trial (EMBARK)) Adult patients with prostate cancer who had biochemical recurrence after local therapy and meet the following criteria at screeni

20 Nov

Chronic Lymphocytic Leukemia

New Indication: Pirtobrutinib in CLL

Open-label, multi-center Phase 1/2 study (BRUIN) Relapse/Refractory CLL/SLL who had previously received a BTK inhibitor Pirtobrutinib (n=317)

20 Nov

Biliary Tract Cancer

New Indication: Trastuzumab plus CISplatin-Gemcitabine in Biliary Tract Cancers

Investigator-initiated, open-label, single-arm, multi-institutional, phase II trial (TAB) Adult patients with HER2-positive, treatment-naïve BTCs Trastuzumab + Gemcitabine + Cispl

20 Nov

Non-Small Cell Lung Cancer

New Indication: Osimertinib in First-Line NSCLC

Multi-center, phase 2 nonrandomized clinical trial (UNICORN) Previously untreated patients with metastatic NSCLC harboring uncommon EGFR mutations, excluding exon 20 insertion muta

20 Nov

Thyroid Cancer

New Drug: Selpercatinib in RET-mutant Medullary Thyroid Cancer

Phase 3, randomized trial (LIBRETTO-531) RET mutant, unresectable, locally advanced or metastatic medullary thyroid cancer and no history of treatment with kinase inhibitors Selpe

20 Nov

Bladder Cancer

New Indication: Erdafitinib in Advanced FGFR Altered Urothelial Cancer

Phase 3, randomized trial, multicenter ttrial ( THOR) FGFR-altered metastatic urothelial carcinoma whose disease progressed after one or two previous treatments that included an a

20 Nov

Non-Small Cell Lung Cancer

New Indication: Perioperative Durvalumab for NSCLC

A Phase III, double-blind, placebo-controlled, multicenter, international Study (AEGEAN) Resectable Stages IIA to IIIB Non-small Cell Lung Cancer Perioperative Durvalumab + Chemot

20 Nov

Mesothelioma

New Indication: Lenvatinib with Pembrolizumab in Pleural Mesothelioma

Single-arm, single-centre, phase 2 study (PEMMELA) Pleural mesothelioma, who progressed after chemotherapy Pembrolizumab + Lenvatinib (n=38)

20 Nov

Colorectal Cancer

New Indication: Sotorasib with Panitumumab in kRAS G12C Mutated Colorectal Cancer

Phase 3, multicenter, open-label, randomized, active-controlled trial (CODEBREAK 300) KRAS G12 C mutant metatatic colorectal cancer, were disease progression or recurrence after r

Easiest Access to Our Chemotherapy Protocol Library

Download our mobile app on iOS or Android to easily access our cancer protocol library, calculate chemotherapy doses, staging library, and access to the reference summaries